OncBioMune Pharmaceuticals Inc (OBMP)

OTC Markets
0.7700
+0.0100(+1.32%)
  • Volume:
    1,426
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.7700 - 0.7700

OBMP Overview

Prev. Close
0.76
Day's Range
0.77-0.77
Revenue
20K
Open
0.77
52 wk Range
0.1123-10
EPS
-12.96
Volume
1,426
Market Cap
1.08M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,098
P/E Ratio
-
Beta
2.98
1-Year Change
270.73%
Shares Outstanding
1,398,070
Next Earnings Date
-
What is your sentiment on OncBioMune Pharmaceuticals Inc?
or
Vote to see community's results!

OncBioMune Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

OncBioMune Pharmaceuticals Inc Company Profile

OncBioMune Pharmaceuticals Inc Company Profile

Employees
0

OncBioMune Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company specializes in various cancer therapies. The Company focuses on developing breast and prostate cancer therapeutic vaccines, and a process for the growth of cancer cells and targeted chemotherapies. Its product portfolio consists of approximately three target therapies and a vaccine platform. The Company's lead product, ProscaVax is indicated for prostate cancer. Its focuses on planning Phase II clinical trials of ProscaVax. The Company is also focused on development of its other technologies, such as the paclitaxel-albumin conjugate. It also has a portfolio of targeted therapies, some of which are biosimilars to drugs, including paclitaxel (Abraxane). The Company is focused on the tumor specific immune status of patients both pre and post immunotherapy that uses autologous tumor antigens to immunize patients. The Company focuses on offering Bekunis for constipation and Cirkused for stress.

Read More
  • Any news?
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.